A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.

Trial Profile

A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2013

At a glance

  • Drugs Bardoxolone methyl (Primary) ; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia; Haematological malignancies; Intra-abdominal infections; Malignant melanoma; Pancreatic cancer; Pelvic inflammatory disorders; Respiratory tract infections; Skin and soft tissue infections; Solid tumours; Tuberculosis
  • Focus Pharmacodynamics
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top